A Food and Drug Administration advisory panel rejected expanding the use of Amarin Corp.'s (Nasdaq: AMRN) Vascepa fish oil drug sending the stock price plummeting $3.24 to $1.93.
No Expansion Of Amarin's Vascepa
October 17, 2013 at 14:02 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.